The Keeneland November Breeding Stock Sale concluded its nine-day run in Lexington Wednesday with vibrant trade from a diverse buying bench leading to across-the-board increases where were highlighted ...

A total of 105 head sold for $8,620,500, with an average of $81,325 and a median of $47,500. The median and average were up ...

To determine the type and severity of a cancer, pathologists typically analyze thin slices of a tumor biopsy under a ...

Positive 270-day Interim Clinical Study Data for the First Subject and Positive 180-day Interim Clinical Study Data for the Second Subject Treated with the Low-Dose of BB-301 in the Phase 1b/2a ...

Becomes first company to showcase four routes of synthesis for approved siRNA therapeutic asset——Joint poster with Bachem demonstrates ...

Novavax incurred a third-quarter 2024 loss of 76 cents per share, narrower than the Zacks Consensus Estimate of a loss of 87 cents. In the year-ago quarter, the company reported a loss of $1.26 per ...

University of Washington-led research, published in 2023, discovered microglia in the brains of people with Alzheimer's ...

A new study presents "Evo" – a machine learning model capable of decoding and designing DNA, RNA, and protein sequences, from ...

Gene therapy can effectively treat various diseases, but for some debilitating conditions like muscular dystrophies there is ...

Neoantigen DNA vaccines are safe and capable of inducing neoantigen-specific immune responses in patients with tripl ...

Gene mutations have consequences both good and bad—from resistance to conditions like diabetes to susceptibility to certain ...